Scarica l'app Stockscreener
36.68
1.49%
0.54
Dopo l'orario di chiusura:
36.68
Neurogene Inc Borsa (NGNE) Ultime notizie
Neurogene Inc. $NGNE Shares Bought by Renaissance Technologies LLC - MarketBeat
Neurogene Inc. (NGNE): Redmile Group and Jeremy Green disclose 9.9% stake - Stock Titan
Neurogene (NGNE) filers disclose 714,885-share Trails Edge stake at 4.5% - Stock Titan
Q3 Earnings Forecast for Neurogene Issued By HC Wainwright - marketbeat.com
Balyasny Asset Management (NGNE) discloses 5.18% Neurogene stake via Atlas fund - Stock Titan
A Quick Look at Today's Ratings for Neurogene(NGNE.US), With a Forecast Between $63 to $166 - Moomoo
Analysts Offer Insights on Healthcare Companies: Neurogene (NGNE) and Cardiff Oncology (CRDF) - The Globe and Mail
Neurogene (NASDAQ:NGNE) Given New $166.00 Price Target at Canaccord Genuity Group - MarketBeat
Neurogene Maintained at Buy as Rett Program Progress and Strong Cash Runway Offset Price Target Trim from $180 to $166 - TipRanks
Neurogene stock price target lowered to $65 by H.C. Wainwright - Investing.com
HC Wainwright Issues Pessimistic Forecast for Neurogene (NASDAQ:NGNE) Stock Price - marketbeat.com
Canaccord lowers Neurogene stock price target on valuation review - Investing.com
William Blair Maintains Neurogene(NGNE.US) With Buy Rating - Moomoo
LifeSci Capital Maintains Neurogene(NGNE.US) With Buy Rating, Cuts Target Price to $63 - Moomoo
Canaccord lowers Neurogene stock price target on valuation review By Investing.com - Investing.com India
TD Cowen Maintains Neurogene(NGNE.US) With Buy Rating - Moomoo
Neurogene Inc. Stock 12‑Month Price Target Cut to $79.75, Implies 118% Upside - TradingView
Neurogene Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Neurogene Inc. Stock 12‑Month Price Target Cut to $78.5, Implies 115% Upside - TradingView
NEUROGENE INC : CANACCORD GENUITY CUTS TARGET PRICE TO $166 FROM $180 - Bitget
Neurogene Q2 Results: EPS widens to $(1.53), misses estimates - scanx.trade
Neurogene (NASDAQ:NGNE) Stock Price Down 7.8% on Disappointing Earnings - MarketBeat
Neurogene (NASDAQ:NGNE) Posts Earnings Results, Misses Expectations By $0.11 EPS - MarketBeat
Neurogene Advances Rett Gene Therapy Program and Extends Cash Runway to 2029 - TipRanks
Form 8K Neurogene Inc For: 11 August By Investing.com - Investing.com Nigeria
Neurogene publishes corporate presentation highlighting NGN-401 gene therapy program for Rett syndrome - Bitget
Neurogene Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Neurogene: Q2 Earnings Snapshot - AOL.com
Neurogene Reports Q2 Net Loss of $34.5 Million - Quiver Quantitative
Neurogene Reports Second Quarter 2026 Financial Results and Highlights Recent Updates - Yahoo Finance
Neurogene (NGNE) Short Interest & Short Float | Updated Aug 2026 - MarketBeat
Neurogene Inc (NGNE) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Neurogene Inc expected to post a loss of $1.42 a shareEarnings Preview - TradingView
Neurogene Inc. (NASDAQ:NGNE) Receives Average Rating of "Buy" from Analysts - MarketBeat
Neurogene (NASDAQ:NGNE): What Should Readers Watch Around Friday’s New Company Catalyst? - Kalkine Media
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
NGNE|Neurogene Inc|Price:34.380|Chg%:+1.510 - TradingKey
Neurogene Inc. Revenue Breakdown – NASDAQ:NGNE - TradingView
NGNE Q2'26 Earnings: revenue estimate is 0 USD - TradingView
Neurogene Inc (NGNE) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Neurogene Inc (NGNE) Institutional Confidence - TradingKey
NGNE|Neurogene Inc|Price:34.610|Chg%:-0.290 - TradingKey
Neurogene Inc (NGNE) Cash Flow - TradingKey
Neurogene Inc (NGNE) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Neurogene Inc (NGNE) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Neurogene Inc (NGNE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
ETFs Investing in Neurogene Inc. Stocks - TradingView
TradingKey - TradingKey
Neurogene Inc (NGNE) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Neurogene Completes $143.7 Million Public Offering of Shares and Pre-Funded Warrants - Global Legal Chronicle
Neurogene prices $125M equity offering - MSN
Neurogene Inc. (NGNE) Q1 2026 Earnings: EPS Miss and No Revenue Highlight Pre-Commercial ChallengesROA Comparison - dars.gov.et
This $20 Biotech Stock Just Got An FDA Boost – And A $200 Price Target - Stocktwits
Neurogene Advances Pivotal Gene Therapy Trial, Embodying Houston's Dynamic Life Sciences Ecosystem - Greater Houston Partnership
LifeSci Capital Maintains Neurogene(NGNE.US) With Buy Rating, Maintains Target Price $65 - Moomoo
Neurogene Surges To A New 52-Week High: Will NGN-401 Reshape The Rett Syndrome Market? - RTTNews
Rett gene therapy drives lasting developmental gains: Long-term data - Rett Syndrome News
Neurogene president & CFO Cvijic sells $173,375 in stock - Investing.com
Insider Sell: Christine Cvijic Sells 4,800 Shares of Neurogene I - GuruFocus
Neurogene president & CFO Cvijic sells $173,375 in stock By Investing.com - Investing.com Nigeria
Form 4 Neurogene Inc For: 7 July By Investing.com - Investing.com Nigeria
Neurogene (NGNE) CFO sells 4,800 shares and retains 84,040 including RSUs - Stock Titan
1.80%
1.77%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):